Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Executive Summary
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q4 2014
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Medtech M&A: Mid-Tiers Poised To Strike In 2015
This may be the year that mid-sized medtech companies step up their acquisition pace to better compete against larger rivals. To be sure, these players won’t rival Medtronic, Covidien, or the other pre-megamerger partners in size or scope, but they could be in a great position to scoop up smaller companies and technologies in a bid to widen or extend their own pipelines.
Medtech M&A: Mid-Tiers Poised To Strike In 2015
This may be the year that mid-sized medtech companies step up their acquisition pace to better compete against larger rivals. To be sure, these players won’t rival Medtronic, Covidien, or the other pre-megamerger partners in size or scope, but they could be in a great position to scoop up smaller companies and technologies in a bid to widen or extend their own pipelines.